Scarlet Therapeutics has raised £3.2 million (€3.7 million) to take therapies based on red blood cells (RBCs) to in vivo proof of concept, building on evidence that natural and lab-grown cells have comparable half-lives.
Tag Archive for: Venture Capital
Cytospire Therapeutics has raised a £61 million (€71 million) Series A round, positioning the British biotech to advance pan-gamma-delta T-cell engagers (TCEs) into cancer clinical trials.
ServierWith the launch of Servier Ventures announced in January and a €200 million commitment to biotech investment, Servier is stepping up its engagement in early-stage innovation in oncology and neurology. European Biotechnology Magazine spoke with Alexis Vandier, Global Head of Servier Ventures, about the fund’s strategy, investment focus, and Europe’s role in the global biotech ecosystem.
Kurma Partners has closed Biofund IV at €215 million, giving European biotech founders a meaningful new source of capital even though the vehicle came in below the €250 million target Kurma set when it launched the fund in October 2024. At first close, Kurma had raised €140 million and said Biofund IV would back 16 to 20 companies, building on the strategy it used in earlier funds.
Boston pic by Lance Anderson via Unsplash, Collage by KnowbioSpain has launched a US$200m venture capital fund anchored in Boston to help Spanish biotech companies scale in one of the world’s foremost life sciences ecosystem. The initiative includes a new trade office in Massachusetts and around US$57m in public seed capital.
Sofinnova PartnersSofinnova Partners has closed its new investment fund, Capital XI, at €650m, far exceeding its original target. The early-stage biotech and medtech-focused fund will invest mostly in Series A, but also seed financings of companies, including oncology, inflammation and immunology, CNS, and cardio-metabolic diseases.
adobe stock photos - Miha Creative VC investments in biotech rose 70.9% in Q3 2025 to US$3.1bn, driven by Series D growth, M&A activity, and Fed interest rate cuts, reports Global Data. J.P. Morgan reports same trends but different figures.
Fuse VectorsFuse Vectors has secured US$5.2m in pre-seed financing to revolutionise gene therapy manufacturing with its cell-free viral vector technology. The Danish company is aiming to make treatments more accessible and cost-effective by streamlining production.
The Swiss biotech sector proved robust growth in 2023. Revenues in 2023 increased by CHF500m to CHF7.3bn. Capital investment grew to CHF2bn – just betweeen 2021 (CHF3.4bn) and 2022 (CHF1.3bn).
Pixabay.comAndera Partners, Paris based European private equity player, announced on Wednesday that, together with RA Capital Management, it is leading an oversubscribed and up-sized $118m Series B financing for Mineralys Therapeutics, Inc., Philadelphia (USA), a private, clinical-stage biopharmaceutical company developing novel therapy for the treatment of hypertension.